A new trading day began on Tuesday, with Lineage Cell Therapeutics Inc (AMEX: LCTX) stock price up 6.84% from the previous day of trading, before settling in for the closing price of $1.17. LCTX’s price has ranged from $0.37 to $1.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -2.93% over the last five years. Meanwhile, its annual earnings per share averaged -111.11%. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 43.20%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.02 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -111.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.25% during the next five years compared to -2.93% drop over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Here are Lineage Cell Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Analysing the last 5-days average volume posted by the [Lineage Cell Therapeutics Inc, LCTX], we can find that recorded value of 1.19 million was lower than the volume posted last year of 1.9 million. As of the previous 9 days, the stock’s Stochastic %D was 69.04%.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 93.65%, which indicates a significant increase from 83.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0835 in the past 14 days, which was higher than the 0.0688 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0335, while its 200-day Moving Average is $0.6930. Now, the first resistance to watch is $1.3000. This is followed by the second major resistance level at $1.3500. The third major resistance level sits at $1.4000. If the price goes on to break the first support level at $1.2000, it is likely to go to the next support level at $1.1500. Should the price break the second support level, the third support level stands at $1.1000.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
With a market capitalization of 285.45 million, the company has a total of 228,356K Shares Outstanding. Currently, annual sales are 9,500 K while annual income is -18,610 K. The company’s previous quarter sales were 2,770 K while its latest quarter income was -30,460 K.
